Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

SpyGlass Pharma Q3 2026 Results: Net Loss of $24.3M, Loss Widens

SpyGlass Pharma reported a net loss of $57.9 million for the nine months ended September 30, 2026, compared to $27.3 million in the prior year, driven by increased R&D and G&A expenses. The company significantly strengthened its balance sheet through an initial public offering and the conversion of preferred stock, ending the period with $208.7 million in cash and cash equivalents.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Profit before tax-24.3-9.8
Net income-24.3-9.8
EPS (diluted, $ a share)$-0.73$-4.53

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Source

10-Q filed with the SEC, NASDAQ: SGP. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

SpyGlass Pharma, Inc.: key numbers

Share price
$31.43Close, Nov 17
Market cap
$1.05B
Shares outstanding
33.46MLatest SEC cover page
Sector
Industrial Applications and Services
Industry
Surgical & Medical Instruments & ApparatusSIC 3841

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from SpyGlass Pharma, Inc.

All →
8:26 AM ET 8-K
Financial Results

SpyGlass Pharma Financial Results

SpyGlass Pharma reported Q3 2026 financial results, highlighting a cash position of $215.8 million which is expected to fund operations through 2028. The company also announced the $13 million acquisition of Advanced Vision Science to secure IOL manufacturing capacity and reported positive four-year follow-up data from its first-in-human study of the BIM-IOL System.

Term
Q3 2026

“SpyGlass Pharma continued to execute our objectives over the course of the quarter as we aim to alter the treatment paradigm for glaucoma patients. Our underlying sustained drug delivery platform delivered four years of safety and efficacy results in the FIH trial of the BIM-IOL System, demonstrating that it can control IOP with unprecedented durability.”

Patrick Mooney, chief executive officer of SpyGlass Pharma
4:10 PM ET 8-K
Clinical Trial Data

SpyGlass Pharma Clinical Trial Data

SpyGlass Pharma announced positive 4-year interim results from its first-in-human trial of the BIM-IOL System for glaucoma patients undergoing cataract surgery. The data showed a 37% reduction in mean intraocular pressure and 86% of patients remained off topical drops with no product-related adverse events reported.

Term
4 years
8:16 AM ET 8-K
M&A Deal

SpyGlass Pharma Signs $13M M&A Deal with Advanced Vision Science, Inc.

SpyGlass Pharma acquired 100% of the equity of Advanced Vision Science, Inc. (AVS) from Santen Holdings US for approximately $13 million in cash. The deal secures internal manufacturing capacity for the intraocular lenses (IOL) used in SpyGlass's Phase 3 drug delivery system and includes a supply agreement to continue providing products to Santen in Japan.

Value
$13M
Counterparty
Advanced Vision Science, Inc.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.